APA (7th ed.) Citation

AT, L., & SI, O. (2023, July). ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia. Lung Cancer: Targets and Therapy.

Chicago Style (17th ed.) Citation

AT, Lee, and Ou SI. "ALESIA 5-Year Update: Alectinib at 600 Mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia." Lung Cancer: Targets and Therapy Jul. 2023.

MLA (9th ed.) Citation

AT, Lee, and Ou SI. "ALESIA 5-Year Update: Alectinib at 600 Mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia." Lung Cancer: Targets and Therapy, Jul. 2023.